FDA
-
-
-
-
-
-
-
Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update
-
-
-
-
-
-
-
Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
-
-
-
-
-
-
-
FDA grants Fast Track status to Corbus' CRB-701 for head and neck cancer
-
-
-
-
-
-
-
Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update
-
-
-
-
-
-
-
Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC
-
-
-
-
-
-
-
Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Akari Therapeutics Appoints Rachelle Jacques as President and Chief Executive Officer
-
325,738 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

